For personal use only

9 October 2025

EVE RAISES $1.1M TO ACCELERATE LAUNCHES OF DYSPRO AND LIBBO

- $1.1 million raised through a placement to sophisticated and professional investors.
- Proceeds to support the commercial rollout of Dyspro™ and Libbo™, including prescriber engagement and market education.
- Funding to support progression to TGA Export-Only registration and full TGA ARTG listing submission.
- Placement reflects strong investor confidence in EVE's commercial and pharmaceutical strategy.
- Placement received bids in excess of the amount sought, demonstrating robust investor demand.

EVE Health Group Limited (ASX: EVE, EVE or the **Company)** is pleased to announce the successful completion of a $1.1 million placement (before costs) to sophisticated and professional investors.

The funds raised will be used to accelerate the commercial rollout of EVE's lead pharmaceutical products, Dyspro™, which launched in September and is the Company's proprietary cannabinoid-based gummy for dysmenorrhoea and endometriosis, and Libbo™, an oral dissolving film for erectile dysfunction. Both products utilise EVE's proprietary nano-emulsion delivery platform designed to improve absorption and accelerate onset. Together these products target global markets exceeding US$16 billion annually.[1] [2]

The proceeds will enable EVE to expand prescriber education programs, grow prescriber and distribution networks, and support ongoing marketing and patient access initiatives following the first patient prescriptions of Dyspro™. Funds will also support the progression to TGA Export-Only status and full TGA registration.

EVE Executive Director and Chief Scientific Officer, Dr Stuart Gunzburg said: "This placement reflects strong support for EVE's vision to transform how everyday conditions in women's and men's health are treated. With Dyspro™ already reaching patients and Libbo™ on track for launch, these funds allow us to accelerate market adoption. We are now in a position to broaden access and awareness while continuing to build the clinical and commercial foundation for these products."

[1] IMARC Group, Dysmenorrhea Market Outlook 2025–2035, March 2025
[2] Coherent Market Insights, Erectile Dysfunction Market Insight, 2025

The placement received bids in excess of the $1.0 million initially sought. Consequently, the Company expanded the offer to $1.1 million, being the maximum capacity available under ASX Listing Rule 7.1.

A total of 36,666,667 new fully paid ordinary shares will be issued at $0.030 per share ("Placement Shares"). Investors will also receive one (1) free attaching unlisted option for every two (2) Placement Shares, exercisable at $0.060 and expiring two years from the date of issue ("Placement Options"). The new shares will be issued under EVE's existing placement capacity pursuant to ASX Listing Rule 7.1, and the attaching options will be issued subject to shareholder approval.

SP Corporate Advisory Pty Ltd (Spark Plus) acted as Lead Manager to the placement.

Authorised for release by the Board of Directors.

Company enquiries
+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group
EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

For personal use only